Loading market dashboard
Zimmer Biomet Holdings, Inc.
ZBHHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption.
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cwm LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 60.8% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 9,377 shares of the medical equipment provider's stock after selling 14,532 shares during the period. Cwm LLC's holdings in Zimmer Biomet
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported upbeat earnings for the first quarter on Tuesday.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet tops Q1 EPS and revenue estimates with strong segment growth and margin expansion, yet shares slip 1.8% premarket after results.
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago.
Zimmer Biomet on Tuesday raised its 2026 adjusted profit forecast after reporting better-than-expected quarterly results, helped by strong demand for its medical devices and new product launches.
First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basis First quarter diluted earnings per share were $1.22, an increase of 34.1%; adjusted1 diluted earnings per share were $2.09, an increase of 15.5% Company updates full-year 2026 financial guidance WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2026.
Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart the company effective April 28 for a new professional opportunity.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH heads into Q1 results with steady EPS estimates, strong knee/hip demand trends and robotics momentum.
Generation Alpha (OTCMKTS:GNAL - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Analyst Recommendations This is a summary of current
Douglas Lane and Associates LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 6.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 460,178 shares of the medical equipment provider's stock after purchasing an additional 28,818 shares during
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m.
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M.
Aberdeen Group plc reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 3.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,309 shares of the medical equipment provider's stock after selling 6,740 shares during
SNDL (NASDAQ: SNDL - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability. Risk and Volatility SNDL has a beta of 0.81,
First Community Trust NA lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 77.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,107 shares of the medical equipment provider's stock after selling 7,050 shares during the period. First Community Trust NA's
Zimmer Biomet Holdings, Inc. (NYSE: ZBH - Get Free Report) has been given a consensus rating of "Hold" by the twenty-two research firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have given a buy rating and
SG Americas Securities LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 69.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 103,462 shares of the medical equipment provider's stock after purchasing an
ZBH leans on knee growth, robotics innovation and steady markets, but debt levels and stiff competition complicate its near-term investment appeal.
Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that have dragged the stock market down for four consecutive weeks still in place. While we have had a virtual March Madness in stocks,... Here Are Monday's Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More.
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Profitability This table compares Capricor Therapeutics and Zimmer
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
